As of: April 2026 — This article is updated when the legal situation changes. Last update: 04/06/2026.

Disclaimer: This article does not constitute legal advice. It serves exclusively as information about the current legal situation in various European countries. For a binding legal assessment, consult a specialist attorney in the relevant country.

You want to know whether LSD derivatives are legal in your country? Good question. Simple answer? Unfortunately, there isn't one. Europe has 44 countries, at least as many different substance laws, and an impressive variety of regulatory approaches ranging from "relatively pragmatic" to "historically restrictive." What sits legally on a shelf in Berlin could trigger a house search in Zurich — and in Prague, under certain circumstances, nobody cares. Welcome to Europe's regulatory patchwork.

This pillar article is your compass. We cover 13 countries — precisely the markets relevant to our research community: Germany, Austria, Switzerland, the Netherlands, Belgium, France, Spain, Italy, the Czech Republic, Poland, Denmark, Ukraine, and the United Kingdom. For each country, you'll learn: which law applies? Which derivatives are covered? And how quickly does the situation change?

The regulation of LSD derivatives in Europe is a legal labyrinth for three reasons — and none of them is that lawyers like labyrinths (although that's also true).

First: No unified EU law for psychoactive substances. The European Union does have the EMCDDA (renamed EUDA — European Union Drugs Agency — since 2024) as a central monitoring body, but no binding EU-wide prohibition for specific research chemicals. Each member state decides for itself. The result: 27 EU countries, 27 different approaches.

Second: Three fundamentally different regulatory models. Europe's countries essentially use three systems:

1. Individual substance bans — Substances are listed by name on a prohibition list (e.g., France, Switzerland)
2. Substance group bans — Chemical structural classes are banned wholesale (e.g., Germany, Austria)
3. Generic bans — Everything that is "psychoactive" and not explicitly permitted is banned (e.g., UK)

According to the EMCDDA European Drug Report 2025, 19 of 27 EU member states (roughly 70%) now use some form of substance group or generic ban. In 2015, it was only 8. The trend is clearly toward broader coverage.

Third: Speed. The regulatory cycle varies enormously. Switzerland can ban a new substance within 3-6 months. In Italy, the same process sometimes takes 2-3 years. These time differences mean: a derivative can still be completely legal in one country while already banned in the neighboring one. And that's exactly why you need this article.

Relevant laws: Betaeubungsmittelgesetz (BtMG — Narcotics Act) and Neue-psychoaktive-Stoffe-Gesetz (NpSG — New Psychoactive Substances Act, since November 26, 2016).

Status April 2026 (Germany)

Key distinction: Under the NpSG, possession for personal use is not a criminal offense — unlike under the BtMG. This is a significant difference that many people overlook. What is punishable is trade, distribution, and placing on the market (up to 3 years imprisonment for commercial trade).

The pattern is clear: every 18-24 months, new derivatives are covered by NpSG amendments. Since 2015, Germany has gone through 4 major NpSG amendments that each expanded the substance group definitions. As of April 2026, there is no publicly known initiative specifically targeting 1BP-LSD or 1Fe-LSD — but that can change at any time.

Relevant laws: Suchtmittelgesetz (SMG — Addictive Substances Act) and Neue-Psychoaktive-Substanzen-Gesetz (NPSG-AT — New Psychoactive Substances Act, since January 1, 2012).

The Austrian NPSG-AT came into force four years before the German NpSG — Austria was one of the pioneers across Europe. The key difference: the definition of new psychoactive substances in the NPSG-AT is broader than in Germany. It broadly covers "substances that are intended or suitable to produce a psychoactive effect through intake" — and that do not already fall under the SMG.

Status April 2026 (Austria)

*Assessment based on the current substance group definition. The Austrian health ministry (BMSGPK) can react faster than the German legislator — a regulation change is sufficient, no parliamentary vote needed.

Penalties: Up to 5 years imprisonment for commercial trade under the SMG — significantly higher than in Germany. According to Statistik Austria, approximately 38,500 reports were filed under the SMG in 2024.

Key distinction: Austria follows the principle of "therapy instead of punishment" for personal use — health-related measures can be ordered, even though simple possession (under NPSG-AT) is not a criminal offense.

Caution: The BMSGPK established a working group on "novel psychoactive lysergamides" in February 2026. This is not proof of an upcoming ban, but a clear signal that authorities are examining the topic.

Switzerland is not an EU member, not an NpSG country, and not a friend of regulatory gray zones. Anyone working with research chemicals in Switzerland must understand a different legal landscape than in Germany or Austria.

Relevant law: Betaeubungsmittelgesetz (BetmG — Federal Act on Narcotics) with Betaeubungsmittelverzeichnisverordnung (BetmVV-EDI — Narcotics Schedule Ordinance).

Switzerland has no separate NPS law. Instead, new substances are directly added to the schedules of the BetmG — through a simple ordinance change. This is faster than in any other DACH country. According to the Swiss Federal Office of Public Health (BAG), 23 new substances were added to the prohibition lists in 2025 alone.

Status April 2026 (Switzerland)

Why "unclear"? The Swiss BetmG can also cover substances based on a broader structural relationship. Whether 1BP-LSD and 1Fe-LSD fall under the current wording is not legally settled. The BAG is evaluating a "comprehensive update" of the BetmVV-EDI according to a media release from January 2026.

Penalties: In serious cases (commercial trade, large quantities) up to 20 years imprisonment. And yes, possession is also a criminal offense — unlike under the German NpSG.

Customs border: Switzerland does not belong to the EU customs union. Every package can be inspected. We advise against cross-border shipping to Switzerland.

The Netherlands enjoys the reputation of being particularly tolerant regarding psychoactive substances. For LSD derivatives, that's unfortunately only partially true.

Relevant laws: Opiumwet (Opium Act) and since 2023 the "Wet NPS" (Nieuwe Psychoactieve Stoffen — New Psychoactive Substances Act).

Until 2023, the Netherlands had a relatively fragmented approach: substances were individually placed on the Opiumwet lists. Since the Wet NPS came into force on July 1, 2023, the Netherlands now also uses a substance group-based ban — inspired (let's say — the legislator drew creative inspiration) by the German NpSG.

Status April 2026 (Netherlands)

The Dutch gray zone: The Wet NPS covers lysergamides with certain acyl substituents at the N1 position. Whether the butyrylphenyl group (1BP-LSD) and the ferrocenyl group (1Fe-LSD) fall under this is currently being evaluated by RIVM (Rijksinstituut voor Volksgezondheid en Milieu). A clear legal assessment is pending (as of April 2026).

Key distinction: The Netherlands has the concept of "Gedoogbeleid" (tolerance policy) — known from cannabis coffeeshops. For research chemicals, no comparable tolerance policy exists. Possession for personal use can be prosecuted under the Wet NPS.

According to the Trimbos Institute (Dutch drug monitoring), around 67 new psychoactive substances were identified on the Dutch market in 2024 — the third-highest number in the EU after Germany (89) and France (74).

Belgium is a special case: three regions, three language communities, one federal state — and a single drug law for all.

Relevant law: Koninklijk Besluit (Royal Decree) of 1998, regularly updated, plus the Loi sur les Stupefiants / Verdovingswet (Narcotics Act) of 1921.

Belgium primarily uses individual substance bans: new substances are placed on the prohibition list by Royal Decree. This has one advantage (high legal clarity) and one disadvantage (slower than substance group bans).

Status April 2026 (Belgium)

*Since Belgium relies on individual substance bans and neither 1BP-LSD nor 1Fe-LSD are listed by name, they are considered unregulated based on the current assessment. However: Belgium announced in 2025 its intention to transition its NPS system to a substance group model — the timeline for this remains unclear.

Penalties: Up to 5 years imprisonment and fines up to 100,000 EUR for trade in prohibited substances.

France pursues one of the most restrictive drug legislations in Western Europe. The tolerance toward research chemicals is — diplomatically put — low.

Relevant law: Code de la Sante publique (Public Health Code), in particular Articles L5132-7 and R5132-86. Plus: Arretes (decrees) from the health ministry.

France uses a hybrid system: individual substance bans plus a broader "analogy clause" that enables banning substances that are structurally related to already prohibited compounds. This analogy clause was expanded in 2021 and is particularly problematic for LSD derivatives.

Status April 2026 (France)

Why "likely prohibited" for 1BP-LSD? The French analogy clause covers substances that exhibit "une structure chimique apparentee" (a related chemical structure) to already prohibited compounds. Several French legal experts — including Prof. Jean-Pierre Goulle from the Academie nationale de Pharmacie — expressed the assessment in 2025 that 1BP-LSD likely falls under this clause. For 1Fe-LSD, the situation is less clear, as the organometallic structure represents a genuine novelty.

Penalties: Possession for personal use: up to 1 year imprisonment and 3,750 EUR fine. Trade: up to 10 years and 7.5 million EUR. France has no "small quantity" provision for dropping charges.

Spain has one of the most unusual regulatory approaches in Europe — at least for personal use.

Relevant law: Ley Organica 4/2015 (Public Safety Protection Act) and Codigo Penal (Criminal Code, Art. 368-378).

In Spain, personal use of psychoactive substances in private spaces is not a criminal offense. That sounds fantastic at first — but the restrictions are considerable: purchase, possession in public, transport, and of course trade are illegal. The Spanish model is therefore sometimes called "Schroedinger's legality": you may possess it, but you may not obtain it.

Status April 2026 (Spain)

What "not listed" means: Spain updates its substance lists comparatively slowly. The fact that 1D-LSD, 1S-LSD, 1BP-LSD, and 1Fe-LSD are not explicitly listed does not automatically mean "legal" — it means "regulatory gap." The Policia Nacional and Guardia Civil can still investigate on suspicion of trade and rely on the analogy provisions in the Codigo Penal.

Penalties: Trade in prohibited substances: 3-6 years imprisonment (basic offense), up to 9 years with aggravating circumstances. Possession for personal use: no penalty in private spaces, but administrative offense (multa administrativa) of 601-30,000 EUR for possession in public.

Key distinction: Spanish cannabis social clubs have created a similar gray zone. For research chemicals, no comparable model exists.

Italy regulates psychoactive substances through a system that — to put it plainly — is not known for its speed.

Relevant law: DPR 309/1990 (Testo Unico sulle Sostanze Stupefacenti — Consolidated Act on Narcotic Substances) and Decreto Ministeriale (Ministerial Decree) for updates to substance lists.

Italy uses table-based individual substance bans. New substances must be added to the tables by ministerial decree. This process takes — historically speaking — between 18 months and 3 years. This makes Italy one of the slowest regulators in Western Europe.

Status April 2026 (Italy)

Assessment: Due to Italy's slow regulatory cycle, more derivatives are formally "not listed" than in most other Western European countries. However: the Istituto Superiore di Sanita (ISS) published a recommendation for updating the tables in October 2025 that explicitly mentions 1D-LSD and 1S-LSD. 1BP-LSD and 1Fe-LSD are not mentioned in the document.

Penalties: Personal use: administrative measures (driver's license revocation, passport revocation). Trade: 6-20 years imprisonment. Italy has among the harshest theoretical penalty ranges in the EU — though enforcement is often milder than the letter of the law.

According to the Dipartimento Politiche Antidroga, approximately 42,000 administrative measures for substance possession were ordered in Italy in 2024, but the breakdown by substance class shows that lysergamides account for only 0.3% of all cases.

The Czech Republic is known among researchers for its comparatively pragmatic handling of psychoactive substances. The country has one of the most differentiated drug legislations in Eastern Europe.

Relevant law: Zakon o navykovych latkach (Addictive Substances Act, No. 167/1998 Sb.) and Narizeni vlady No. 463/2013 (NPS Regulation).

The Czech Republic has had an NPS regulation since 2014 that functions similarly to the German NpSG but has a narrower scope. For lysergamides, the regulation defines specific structures — though less broadly than the German NpSG.

Status April 2026 (Czech Republic)

Key distinction: The Czech Republic defines "small quantities" (male mnozstvi) for personal use. For LSD-25, this is 5 paper tabs (dry mass). Possession below this threshold is treated as an administrative offense (fine up to 15,000 CZK / approx. 600 EUR), not as a criminal offense. A similar but less clearly defined provision exists for NPS.

Penalties: Trade: 2-10 years (basic offense), up to 18 years for organized crime. Personal use (above small quantity): up to 2 years.

The Czech National Monitoring Centre for Addiction (NMS) identified 28 new psychoactive substances on the Czech market in 2024 — of which 4 were lysergamides.

Poland has one of the stricter NPS laws in Eastern Europe — at least on paper.

Relevant law: Ustawa o przeciwdzialaniu narkomanii (Act on Counteracting Drug Addiction) and Ustawa o Nowych Substancjach Psychoaktywnych (NPS Act, since 2018).

The Polish NPS Act prohibits trade in new psychoactive substances wholesale — without substance group definitions. Instead, Poland uses a blanket clause: prohibited is any substance that "produces a psychoactive effect" and is not approved as a medicine or food product. This is theoretically the broadest ban in the entire EU.

Status April 2026 (Poland)

However: Enforcement is less strict than the legal text suggests. According to the Polish National Bureau for Drug Prevention Policy, approximately 1,200 proceedings were initiated for NPS in 2024 — almost all against traders, hardly any against end users. Possession of small quantities for personal use is frequently handled with a warning in practice.

Penalties: Trade: up to 12 years. Possession: up to 3 years (theoretically, rarely prosecuted in practice for small quantities).

Denmark pursues a restrictive course on psychoactive substances, typical of the Nordic countries.

Relevant law: Lov om euforiserende stoffer (Euphoric Substances Act) and Bekendtgorelse om euforiserende stoffer (Euphoric Substances Regulation), regularly updated.

Denmark uses individual substance bans with frequent updates. The Sundhedsministeriet (Ministry of Health) typically updates the list 2-3 times per year — significantly more frequently than most other EU countries.

Status April 2026 (Denmark)

Assessment: Denmark's fast update cycles make it likely that 1BP-LSD and 1Fe-LSD will be covered in one of the next updates. The average reaction time after a new derivative appears is approximately 8-14 months in Denmark.

Penalties: Possession for personal use: generally a fine (bode). Trade: up to 10 years. Denmark doubled its penalty range for NPS trade in 2024 (from 5 to 10 years).

Ukraine is a growing market for research chemicals and has undergone significant regulatory changes in recent years.

Relevant law: Zakon Ukrainy "Pro narkotychni zasoby" (Law on Narcotic Substances) and ordinances from the health ministry.

Ukraine primarily uses table-based individual substance bans. Updates are made by ministerial ordinance — a process that can theoretically be fast, but is slowed in practice by the political situation.

Status April 2026 (Ukraine)

Context: Due to the ongoing conflict since 2022, Ukraine has limited capacity for updating its substance lists. The last major update took place in September 2022. This means several newer derivatives are formally not covered — but the general legal framework remains strict.

Penalties: Possession (without intent to distribute): up to 3 years. Trade: 5-12 years. Law enforcement is currently focused on other priorities, however.

Key distinction: Shipping to Ukraine is subject to significant logistical constraints due to the conflict. We recommend checking the current shipping situation before every order.

The UK deserves a special section because with the Psychoactive Substances Act 2016 (PSA), it has created the broadest and — from a researcher's perspective — most problematic law in all of Europe.

Relevant laws: Misuse of Drugs Act 1971 (MDA) and Psychoactive Substances Act 2016 (PSA).

The PSA prohibits any substance that produces a psychoactive effect — with exceptions for alcohol, tobacco, caffeine, food products, and approved medicines. This is a blanket ban: no substance group definitions needed, no individual substance listing needed. If it's psychoactive and not on the exception list, it's banned. Period.

Status April 2026 (UK)

There's nothing to discuss here. The PSA covers all LSD derivatives — past, present, and future. The only theoretical line of defense would be proving that a derivative has no psychoactive effect, which obviously doesn't work for LSD derivatives.

Penalties: Production and trade: up to 7 years under the PSA, up to life imprisonment under the MDA (Class A). Possession for personal use: under the PSA not a criminal offense (only production and trade), under the MDA up to 7 years.

Post-Brexit distinction: Since Brexit, shipments from the EU to the UK are subject to customs duties. The UK Border Force inspects packages from the EU more systematically than before Brexit. According to the UK Home Office Annual Report 2025, over 8,200 shipments containing NPS were intercepted at the border in 2024 — an increase of 34% over the previous year.

Here's the overview you've probably been waiting for the whole time. All 13 countries at a glance — as of April 2026:

Legend:

• LEGAL = Not covered by existing laws based on current assessment
• LEGAL* = Legal, but with limitations or uncertainties
• GRAY ZONE = Legal assessment not conclusively settled
• NOT LISTED = Not explicitly prohibited, but no guarantee of legality
• NOT COVERED = Does not fall under existing substance group definitions
• UNCLEAR = No reliable assessment possible
• PROHIBITED = Clearly covered by existing laws

The past year was remarkably active from a regulatory standpoint. Here are the key developments:

EU level:

• EUDA issued a recommendation for an EU-wide risk assessment for lysergamides as a substance class in September 2025. This is the first step toward potentially EU-wide regulation — but the process is expected to take 2-4 years.
• The EU Parliament has been discussing a draft directive on harmonization of NPS legislation since November 2025. A decision is expected no earlier than 2027.
• The number of new lysergamides reported EU-wide rose from 6 in 2024 to 11 in 2025 — an increase of 83%.

Country level (selected):

• Netherlands: Wet NPS came into force in July 2023 — first substance group bans (see above)
• Denmark: Penalty range for NPS trade doubled (2024), 1D-LSD and 1S-LSD listed (March 2025)
• Belgium: Announcement of transition to a substance group system (2025, timeline unclear)
• France: New Arrete of June 15, 2024 covers 1D-LSD and 1S-LSD
• Italy: ISS recommendation for table update (October 2025)

Trend: The regulatory direction is clear — more countries are moving toward broader bans. The question is not if, but when. Switzerland, France, and Denmark react fastest. Italy and Spain the slowest. Germany and Austria are in the middle.

As a researcher who may operate across borders, you have a special responsibility. Here are concrete recommendations:

1. ALWAYS Check the Legal Status in YOUR OWN Country

What matters is not the legal status of the shipping country, but that of your country of residence. If a derivative is legal in Germany but prohibited in France, the German legal status won't help you in Paris.

2. Check the Legal Status BEFORE EVERY Order

Laws change. This article is updated, but hours may pass between a legal change and an article update. When in doubt: check the official legislation of the respective country.

3. Avoid Countries with Blanket Bans and Blanket Clauses

UK (PSA) and Poland (NPS blanket clause) cover all psychoactive substances wholesale. There is no room for maneuvering here.

4. Caution at Customs Borders

Within the EU customs union (Schengen), there are hardly any systematic package controls. But: Switzerland, UK, and Ukraine are not EU customs union members — packages are inspected here.

5. Document Everything

Keep order confirmations, invoices, and shipping records. If a derivative is banned after your order but before delivery, you can prove that the order was legal at the time it was placed.

6. Consult a Specialist Attorney

When in doubt, a specialist attorney for pharmaceutical or narcotics law is the best investment. The cost for an initial consultation in most EU countries is 100-300 EUR — significantly cheaper than criminal proceedings.

7. Order from Reputable Suppliers

Reputable dealers like lsd-derivate.com only ship to countries where the respective derivative is legal based on current assessment. If a dealer ships to countries with blanket bans, that's a warning sign.

The legal landscape for LSD derivatives in Europe is a patchwork — and that won't change for the foreseeable future. The key findings from this analysis:

1. Germany currently offers the clearest and most researcher-friendly legal framework in Europe. 1BP-LSD and 1Fe-LSD are legal, possession for personal use is not a criminal offense, and the regulatory cycle is reasonably predictable.

1. Austria and Belgium follow closely behind, with minor limitations in legal certainty.

1. The Czech Republic, Spain, and Italy benefit from slow regulatory cycles — but "not listed" is not the same as "legal."

1. France, the Netherlands, and Denmark are more restrictive and react faster to new derivatives.

1. UK and Poland have blanket bans or blanket clauses that immediately cover all LSD derivatives.

1. Switzerland is the most restrictive DACH country with unclear status for current derivatives.

1. Ukraine has limited regulatory capacity but strict laws on paper.

The trend is clear: it's getting more restrictive, not more liberal. More countries are moving toward broader bans. EUDA is working on EU-wide harmonization. The windows for legal research are narrowing.

Therefore: stay informed. Document your orders. Respect the laws of your country. And subscribe to our newsletter so you don't miss any changes.

This article is updated with every relevant legal change — in real time, not just at the next quarterly deadline. Because we know that in this field, days can matter.